ArticleBiomaterials2009
The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype.
Article in Biomaterials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 80 citations in OpenAlex.
- Aptamer-functionalized apoptotic vesicles ameliorate osteoarthritis via resuming mitochondria OXPHOS of chondrocytes.Science advances · 2026Article
- Fully Synthetic, Biomimicking Polysulfates With Tunable Anticoagulant and Endothelial Cell-Selective Bioactivity.Macromolecular bioscience · 2026Article
- Review
- Preparation of biocompatibility coating on magnesium alloy surface by sodium alginate and carboxymethyl chitosan hydrogel.iScience · 2024Article
- Construction of multifunctional hydrogel with metal-polyphenol capsules for infected full-thickness skin wound healing.Bioactive materials · 2023Article
- Hemocompatibility Evaluation of ThaiPolymers · 2022Article
- Six Shades of Vascular Smooth Muscle Cells Illuminated by KLF4 (Krüppel-Like Factor 4).Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Effects of recipient age, heparin release and allogeneic bone marrow-derived stromal cells on vascular graft remodeling.Acta biomaterialia · 2021Article
- Article
- Biocompatibility evaluation of heparin-conjugated poly(ε-caprolactone) scaffolds in a rat subcutaneous implantation model.Journal of materials science. Materials in medicine · 2020Article
- Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.Advanced healthcare materials · 2018Review
- Multi-component hybrid hydrogels - understanding the extent of orthogonal assembly and its impact on controlled release.Chemical science · 2017Article
- Article
- Biomimetic-engineered poly (ethylene glycol) hydrogel for smooth muscle cell migration.Tissue engineering. Part A · 2014Article
- Biomaterials in cardiovascular research: applications and clinical implications.BioMed research international · 2014Review
- Multilayered heparin hydrogel microwells for cultivation of primary hepatocytes.Advanced healthcare materials · 2014Article
- Enhancing angiogenesis alleviates hypoxia and improves engraftment of enteric cells in polycaprolactone scaffolds.Journal of tissue engineering and regenerative medicine · 2013Article
- Heparin nanomodification improves biocompatibility and biomechanical stability of decellularized vascular scaffolds.International journal of nanomedicine · 2012Article
- Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.Tissue engineering. Part B, Reviews · 2010Review
- Effect of heparin oligomer chain length on the activation of valvular interstitial cells.Biomacromolecules · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Poly(ethylene glycol) diacrylate (PEGDA) hydrogel scaffolds were engineered to promote contractile smooth muscle cell (SMC) phenotype via controlled release of heparin. The scaffold design was evaluated by quantifying the effects of free heparin on SMC phenotype, engineering hydrogels to provide controlled release of heparin, and synthesizing cell-adhesive, heparin releasing hydrogels to promote contractile SMC phenotype. Heparin inhibited SMC proliferation and up-regulated expression of contractile SMC phenotype markers, including smooth muscle alpha-actin, calponin, and SM-22alpha, in a dose-dependent fashion (6 microg/ml to 3.2mg/ml). Heparin release from PEGDA hydrogels was controlled by altering PEGDA molecular weight (MW 1000-6000) and concentration at polymerization (10-30% w/w), yielding release profiles ranging from hours to weeks in duration. Heparin released from PEGDA gels, formulated for optimized heparin loading and release kinetics (30% w/w PEGDA, MW 3000), stimulated SMCs to up-regulate contractile marker mRNA. A cell-instructive scaffold construct was prepared by polymerizing a thin hydrogel film, with pendant RGD peptides for cell attachment, over the optimized hydrogel depots. SMCs seeded on these constructs had elevated levels of contractile marker mRNA after 3 d of culture compared with SMCs on control constructs. These results indicate that RGD-modified, heparin releasing PEGDA gels can act as cell-instructive scaffolds that promote contractile SMC phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.